Caner Saygin

4.5k total citations
29 papers, 449 citations indexed

About

Caner Saygin is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Caner Saygin has authored 29 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 9 papers in Public Health, Environmental and Occupational Health and 6 papers in Genetics. Recurrent topics in Caner Saygin's work include Acute Myeloid Leukemia Research (13 papers), Acute Lymphoblastic Leukemia research (9 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Caner Saygin is often cited by papers focused on Acute Myeloid Leukemia Research (13 papers), Acute Lymphoblastic Leukemia research (9 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Caner Saygin collaborates with scholars based in United States, Türkiye and Australia. Caner Saygin's co-authors include Didem Uzunaslan, Nükhet Tüzüner, Mustafa Özgüroğlu, Mustafa Şenocak, Hetty E. Carraway, Wendy Stock, Lori Muffly, Hilal Akı, Gülen Hatemi and Haydar Durak and has published in prestigious journals such as Blood, Clinical Cancer Research and Annals of the Rheumatic Diseases.

In The Last Decade

Caner Saygin

27 papers receiving 445 citations

Peers

Countries citing papers authored by Caner Saygin

Since Specialization

Citations

This map shows the geographic impact of Caner Saygin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caner Saygin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caner Saygin more than expected).

Fields of papers citing papers by Caner Saygin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caner Saygin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caner Saygin. The network helps show where Caner Saygin may publish in the future.

Co-authorship network of co-authors of Caner Saygin

This figure shows the co-authorship network connecting the top 25 collaborators of Caner Saygin. A scholar is included among the top collaborators of Caner Saygin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caner Saygin. Caner Saygin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evolution of Clonal Hematopoiesis after Discontinuation of Therapy for Multiple 2024 ·Blood ·Jennifer H. Cooperrider, (unknown), Tadeusz Kubicki, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Andrzej Jakubowiak, Benjamin A. Derman, Caner Saygin	0
2	Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia 2023 ·Clinical Cancer Research ·Caner Saygin, (unknown), (unknown), (unknown), (unknown), Girish Venkataraman, Vijayalakshmi Ananthanarayanan, Tiffaney L. Vincent, Adam DuVall, Anand Patel, (unknown), Fenlai Tan, Stephen P. Anthony, (unknown), Yue Shen, Olatoyosi Odenike, David T. Teachey, Barbara L. Kee, James L. LaBelle, Wendy Stock	10
3	Sequential tumor molecular profiling identifies likely germline variants 2023 ·Genetics in Medicine ·Ira L. Kraft, (unknown), (unknown), (unknown), Caner Saygin, (unknown), Pankhuri Wanjari, Nifang Niu, Soma Das, Jill L. O. de Jong, Jeremy P. Segal, Lucy A. Godley	3
4	Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL 2023 ·Leukemia ·(unknown), (unknown), (unknown), (unknown), Caner Saygin, Wendy Stock, Elizabeth T. Bartom, Barbara L. Kee	1
5	Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors 2023 ·British Journal of Haematology ·(unknown), Adam DuVall, Caner Saygin, Peng Wang, Sandeep Gurbuxani, Richard A. Larson, Wendy Stock, Anand Patel	3
6	Discordance between Next Generation Sequencing and BCR-ABL PCR Measurable Residual Disease in Adult Patients with Ph+ Acute Lymphoblastic Leukemia 2023 ·Blood ·Simone E. Dekker, (unknown), (unknown), Caner Saygin, Marc S. Schwartz, (unknown), Andy Kaempf, Marlise R. Luskin, Anand Patel, Lori Muffly, Jessica Leonard	2
7	Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones 2022 ·Blood Advances ·Afaf E.G. Osman, Nuria Mencia-Trinchant, Caner Saygin, (unknown), (unknown), Genevieve Housman, (unknown), (unknown), (unknown), Duane C. Hassane, Andrea Sboner, (unknown), (unknown), Christopher Johnson, (unknown), Bana Jabrì, (unknown), Mónica L. Guzmán, Pinkal Desai, Lucy A. Godley	8
8	Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies 2022 ·Blood Advances ·Caner Saygin, Gregory W. Roloff, Christopher N Hahn, Rakchha Chhetri, Saar Gill, Hany Elmariah, Chetasi Talati, (unknown), Guimin Gao, (unknown), Michael R. Bishop, Satyajit Kosuri, Soma Das, Deepak Singhal, Parvathy Venugopal, Claire C. Homan, Anna Brown, Hamish S. Scott, Devendra Hiwase, Lucy A. Godley	23
9	B-cell lymphoma-2 downregulation is a useful feature supporting a neoplastic phenotype in mature T-cell lymphomas 2022 ·Human Pathology ·(unknown), (unknown), Kennosuke Karube, (unknown), (unknown), Caner Saygin, (unknown), (unknown), Sandeep Gurbuxani, Daniel A. Arber, Melissa Y. Tjota, Jeremy Segal, Sonali M. Smith, Carlos Murga‐Zamalloa, Girish Venkataraman	3
10	Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients 2022 ·Haematologica ·Caner Saygin, (unknown), Wendy Stock, Lori Muffly	40
11	OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia 2021 ·Blood Cancer Journal ·Bartholomew J. Eisfelder, Caner Saygin, Joseph Wynne, (unknown), Mariafausta Fischietti, Elspeth M. Beauchamp, Jason X. Cheng, Olatoyosi Odenike, Gail J. Roboz, Houda Alachkar, Wendy Stock	9
12	LC-FACSeq is a method for detecting rare clones in leukemia 2020 ·JCI Insight ·Eileen Hu, James S. Blachly, Caner Saygin, Hatice Gülçin Özer, (unknown), Arletta Lozanski, (unknown), Chi‐Ling Chiang, Seema A. Bhat, Kerry A. Rogers, Jennifer A. Woyach, Kevin R. Coombes, Daniel Jones, Natarajan Muthusamy, Gerard Lozanski, John C. Byrd	3
13	Current and emerging strategies for management of myelodysplastic syndromes 2020 ·Blood Reviews ·Caner Saygin, Hetty E. Carraway	39
14	Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq 2019 ·Blood ·Caner Saygin, Arletta Lozanski, (unknown), Shelley Orwick, Deedra Nicolet, (unknown), Nyla A. Heerema, Rosa Lapalombella, Gregory K. Behbehani, John C. Byrd, Gerard Lozanski, James S. Blachly	1
15	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1 2018 ·Blood Cancer Journal ·Caner Saygin, Cassandra M. Hirsch, Bartlomiej Przychodzen, Mikkael A. Sekeres, Betty K. Hamilton, Matt Kalaycio, Hetty E. Carraway, Aaron T. Gerds, Sudipto Mukherjee, Aziz Nazha, Ronald Sobecks, (unknown), (unknown), Jaroslaw P. Maciejewski, Anjali S. Advani	36
16	Suicidal ideation among patients with Behçet's syndrome. 2016 ·PubMed ·Caner Saygin, Didem Uzunaslan, Gülen Hatemi, Vedat Hamuryudan	7
17	Currently Used Biologic Agents in the Management of Behcet’s Syndrome 2015 ·Current Medicinal Chemistry ·Caner Saygin, Didem Uzunaslan, Gülen Hatemi	5
18	No appreciable decrease in fertility in Behçet’s syndrome 2013 ·Lara D. Veeken ·Didem Uzunaslan, Caner Saygin, Gülen Hatemi, Koray Taşçılar, Hasan Yazıcı	19
19	Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival 2013 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Caner Saygin, Didem Uzunaslan, Bülent Önal, Haydar Durak, Hilal Akı	41
20	Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series 2013 ·Critical Reviews in Oncology/Hematology ·Caner Saygin, Didem Uzunaslan, Mustafa Özgüroğlu, Mustafa Şenocak, Nükhet Tüzüner	148

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact